Learn how cryptographic decision records strengthen FDA warning letter responses for AI medical device manufacturers and help avoid consent decree escalation.
An FDA warning letter is one of the most serious regulatory actions short of a consent decree or product seizure. For AI medical device manufacturers, warning letters typically cite systemic deficiencies in quality systems, design controls, or post-market surveillance. The response must demonstrate not just that individual problems have been fixed, but that the underlying quality system has been strengthened to prevent recurrence. InferTrust™ (Patent Pending) FDA Enforcement provides the verifiable evidence infrastructure that warning letter responses require.
Warning letters demand evidence of systemic improvement, not just point fixes. InferTrust™ supports this by providing a verifiable record of every algorithm change, validation event, and performance metric across the entire device portfolio. When the warning letter response claims that change control processes have been strengthened, InferTrust™ decision records prove it with cryptographic evidence of every model update, validation test, and deployment event that has occurred since the corrective action was implemented.
After submitting a warning letter response, manufacturers must maintain the improvements they documented. FDA may conduct a follow-up inspection to verify sustained compliance. InferTrust™ provides continuous, tamper-evident evidence of ongoing compliance: decision records prove that confidence thresholds are being enforced, model updates are following approved change control procedures, post-market surveillance is actively monitoring device performance, and escalation policies are functioning as documented. This ongoing evidence record means the follow-up inspection can verify compliance from the sealed record chain rather than relying on spot-check observations.
If a warning letter response is inadequate, FDA may escalate to a consent decree, which imposes court-ordered compliance requirements and ongoing FDA oversight. The strongest defense against escalation is a response that demonstrates both the corrective action and the infrastructure to sustain it. InferTrust™ provides that infrastructure. Cryptographic decision records give both the manufacturer and FDA confidence that the quality system improvements are real, verifiable, and durable, reducing the likelihood that enforcement escalates beyond the warning letter stage.